新闻源 财富源

2019年10月20日 星期天

誉衡药业(002437)公告正文

誉衡药业:2011年半年度报告摘要

公告日期:2011-08-30

    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    证券代码:002437                              证券简称:誉衡药业                                公告编号:2011-095
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    §1 重要提示
    1.1 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、
    误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    本半年度报告摘要摘自半年度报告全文,报告全文同时刊载于巨潮资讯网(www.cninfo.com.cn)。投
    资者欲了解详细内容,应当仔细阅读半年度报告全文。
    1.2 公司半年度财务报告未经会计师事务所审计。
    1.3 公司负责人朱吉满、主管会计工作负责人杨华蓉及会计机构负责人(会计主管人员)赵金宇声明:
    保证半年度报告中财务报告的真实、完整。
    §2 上市公司基本情况
    2.1 基本情况简介
    股票简称              誉衡药业
    股票代码              002437
    上市证券交易所           深圳证券交易所
    董事会秘书                                证券事务代表
    姓名                王东绪                                    刘畅
    黑龙江省哈尔滨市呼兰区利民经济技术开      北京市朝阳区北苑路 170 号凯旋城 D 座 11
    联系地址
    发区北京路 29 号                          层 1101 室
    电话                010-59711207                              010-59711207
    传真                010-58236767-118                          010-58236767-118
    电子信箱              gloriapharma@126.com                      gloriapharma@126.com
    2.2 主要财务数据和指标
    2.2.1 主要会计数据和财务指标
    单位:元
    本报告期末比上年度期末增减
    本报告期末         上年度期末
    (%)
    总资产(元)                     2,172,547,942.00   2,194,470,048.23                         -1.00%
    归属于上市公司股东的所有者权益(元)         2,114,626,417.67   2,120,742,457.91                         -0.29%
    股本(股)                       280,000,000.00    140,000,000.00                         100.00%
    归属于上市公司股东的每股净资产(元/股)                   7.55             15.15                         -50.17%
    报告期(1-6 月)        上年同期         本报告期比上年同期增减(%)
    营业总收入(元)                     254,966,833.88    236,145,222.90                           7.97%
    1
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    营业利润(元)                         76,308,713.26          72,990,563.26                                    4.55%
    利润总额(元)                         76,243,084.42          73,995,563.26                                    3.04%
    归属于上市公司股东的净利润(元)               63,883,959.76          63,023,794.05                                    1.36%
    归属于上市公司股东的扣除非经常性损益后的
    63,941,384.99          62,144,794.05                                    2.89%
    净利润(元)
    基本每股收益(元/股)                               0.23                     0.30                                -61.67%
    稀释每股收益(元/股)                               0.23                     0.30                                -61.67%
    加权平均净资产收益率 (%)                          3.02%                 19.75%                                    -16.73%
    扣除非经常性损益后的加权平均净资产收益率
    3.02%                 19.51%                                    -16.49%
    (%)
    经营活动产生的现金流量净额(元)               43,586,075.74          43,478,585.26                                    0.25%
    每股经营活动产生的现金流量净额(元/股)                         0.16                     0.21                                -23.81%
    2.2.2 非经常性损益项目
    √ 适用 □ 不适用
    单位:元
    非经常性损益项目                                            金额                         附注(如适用)
    非流动资产处置损益                                                                             -8,798.84
    除上述各项之外的其他营业外收入和支出                                                       -56,830.00
    所得税影响额                                                                                    8,203.61
    合计                                                          -57,425.23                  -
    2.2.3 境内外会计准则差异
    □ 适用 √ 不适用
    §3 股本变动及股东情况
    3.1 股份变动情况表
    √ 适用 □ 不适用
    单位:股
    本次变动前                          本次变动增减(+,-)                                  本次变动后
    发行新                    公积金
    数量          比例                 送股                       其他           小计         数量          比例
    股                      转股
    一、有限售条件股     105,000,                                          105,000,   -25,200,0       79,800,0     184,800,
    75.00%        0             0                                                            66.00%
    份                       000                                               000          00              00         000
    1、国家持股                  0      0.00%         0             0            0             0               0           0      0.00%
    2、国有法人持股              0      0.00%         0             0            0             0               0           0      0.00%
    63,000,0                                          63,000,0                   63,000,0     126,000,
    3、其他内资持股                     45.00%        0             0                          0                                 45.00%
    00                                                00                         00         000
    其中:境内非国     63,000,0                                          63,000,0                   63,000,0     126,000,
    45.00%        0             0                          0                                 45.00%
    有法人持股                 00                                                00                         00         000
    境内自然人
    0      0.00%         0             0            0             0               0           0      0.00%
    持股
    4、外资持股          42,000,0       30.00%        0             0      42,000,0   -25,200,0       16,800,0     58,800,0      21.00%
    2
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    00                                             00           00            00         00
    其中:境外法人     42,000,0                                        42,000,0     -25,200,0     16,800,0    58,800,0
    30.00%        0            0                                                         21.00%
    持股                       00                                              00           00            00          00
    境外自然人
    0        0.00%        0            0              0          0             0          0       0.00%
    持股
    5、高管股份                 0        0.00%        0            0              0          0             0          0       0.00%
    二、无限售条件股     35,000,0                                        35,000,0     25,200,0      60,200,0    95,200,0
    25.00%        0            0                                                         34.00%
    份                         00                                              00           00            00          00
    35,000,0                                        35,000,0     25,200,0      60,200,0    95,200,0
    1、人民币普通股                     25.00%        0            0                                                         34.00%
    00                                              00           00            00          00
    2、境内上市的外
    0        0.00%        0            0              0          0             0          0       0.00%
    资股
    3、境外上市的外
    0        0.00%        0            0              0          0             0          0       0.00%
    资股
    4、其他                     0        0.00%        0            0              0          0             0          0       0.00%
    140,000,                                        140,000,                   140,000,    280,000,
    三、股份总数                       100.00%        0            0                         0                              100.00%
    000                                             000                        000         000
    3.2 前 10 名股东、前 10 名无限售条件股东持股情况表
    单位:股
    股东总数                                                                                                        17,676
    前 10 名股东持股情况
    持有有限售条件股         质押或冻结的股份
    股东名称                 股东性质     持股比例           持股总数
    份数量                     数量
    哈尔滨恒世达昌科技有限           境内非国有法
    44.63%       124,950,000                124,950,000              2,000,000
    公司                             人
    YU HENG
    INTERNATIONAL
    境外法人             21.00%        58,800,000                 58,800,000                     0
    INVESTMENTS
    CORPORATION
    ORIENTAL KEYSTONE
    境外法人             9.00%         25,200,000                         0                      0
    INVESTMENT LIMITED
    中国工商银行 - 博时精选          境内非国有法
    2.24%          6,285,157                         0                      0
    股票证券投资基金                 人
    中国工商银行 - 华安中小
    境内非国有法
    盘成长股票型证券投资基                                0.44%          1,230,000                         0                      0
    人
    金
    百庚禹丰(北京)投资顾问有         境内非国有法
    0.38%          1,050,000                  1,050,000                     0
    限公司                           人
    中国人寿保险股份有限公
    境内非国有法
    司 - 传统 - 普通保险产品                              0.37%          1,032,046                         0                      0
    人
    -005L-CT001 深
    戴诗延                           境内自然人           0.36%          1,000,000                         0                      0
    华润深国投信有限公司 -
    境内非国有法
    尊享权益灵活配置 5 号资金                             0.34%           958,445                          0                      0
    人
    信托
    兴业国际信托有限公司 -
    境内非国有法
    新股申购建行财富第一期                                0.31%           870,000                          0                      0
    人
    (2 期)
    3
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    前 10 名无限售条件股东持股情况
    股东名称                         持有无限售条件股份数量                      股份种类
    ORIENTAL KEYSTONE INVESTMENT
    25,200,000   人民币普通股
    LIMITED
    中国工商银行 - 博时精选股票证券投资基
    6,285,157   人民币普通股
    金
    中国工商银行 - 华安中小盘成长股票型证
    1,230,000   人民币普通股
    券投资基金
    中国人寿保险股份有限公司 - 传统 - 普通
    1,032,046   人民币普通股
    保险产品-005L-CT001 深
    戴诗延                                                                1,000,000   人民币普通股
    华润深国投信托有限公司 - 尊享权益灵活
    958,445    人民币普通股
    配置 5 号资金信托
    兴业国际信托有限公司 - 新股申购建行财
    870,000    人民币普通股
    富第一期(2 期)
    中国建设银行 - 华夏盛世精选股票型证券
    802,259    人民币普通股
    投资基金
    交通银行 - 农银汇理行业成长股票型证券
    768,370    人民币普通股
    投资基金
    刘华                                                                   730,000    人民币普通股
    上述股东关联关系或一致       哈尔滨恒世达昌科技有限公司与誉衡国际属同一实际控制人控制,未知其他股东是否存在关
    行动的说明             联关系,也未知是否属于《上市公司持股变动信息披露管理办法》中规定的一致行动人。
    3.3 控股股东及实际控制人变更情况
    □ 适用 √ 不适用
    §4 董事、监事和高级管理人员情况
    4.1 董事、监事和高级管理人员持股变动
    □ 适用 √ 不适用
    §5 董事会报告
    5.1 主营业务分行业、产品情况表
    单位:万元
    主营业务分行业情况
    营业收入比上    营业成本比上
    毛利率比上年
    分行业或分产品           营业收入      营业成本      毛利率(%)    年同期增减      年同期增减
    同期增减(%)
    (%)           (%)
    医药制造                     12,899.99      2,676.40        79.25%            8.16%         13.77%           -1.02%
    医药流通                     12,075.79      9,676.66        19.87%            5.73%         14.94%           -6.42%
    主营业务分产品情况
    针剂产品                     21,206.27      9,362.32        55.85%            9.20%         15.83%           -2.53%
    口服产品                      3,596.04      2,898.86        19.39%          21.92%          33.25%           -6.86%
    4
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    5.2 主营业务分地区情况
    单位:万元
    地区                                      营业收入                        营业收入比上年增减(%)
    华北地区                                                                       4,013.62                              12.05%
    东北地区                                                                       1,770.60                              18.45%
    华东地区                                                                       6,447.13                              -0.37%
    华中地区                                                                       3,459.16                              -3.57%
    华南地区                                                                       3,611.10                              16.11%
    西南地区                                                                       3,819.57                              19.48%
    西北地区                                                                       1,854.61                              -2.74%
    5.3 主营业务及其结构发生重大变化的原因说明
    □ 适用 √ 不适用
    5.4 主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明
    □ 适用 √ 不适用
    5.5 利润构成与上年度相比发生重大变化的原因分析
    □ 适用 √ 不适用
    5.6 募集资金使用情况
    5.6.1 募集资金使用情况对照表
    √ 适用 □ 不适用
    单位:万元
    募集资金总额                         167,850.00
    本报告期投入募集资金总额                           10,596.72
    报告期内变更用途的募集资金总额                        0.00
    累计变更用途的募集资金总额                          0.00
    已累计投入募集资金总额                            53,363.25
    累计变更用途的募集资金总额比例                      0.00%
    是
    否
    已
    变                                    截至    截至期
    募集                                                                                    项目可
    更                                    期末    末投资                                是否
    资金    调整后投                                      项目达到预      本报告            行性是
    承诺投资项目和超       项                       本报告期     累计      进度                                达到
    承诺      资总额                                      定可使用状      期实现            否发生
    募资金投向           目                       投入金额     投入    (%)(3)                                预计
    投资        (1)                                         态日期        的效益            重大变
    (含                                    金额      =                                  效益
    总额                                                                                      化
    部                                    (2)     (2)/(1)
    分
    变
    更)
    承诺投资项目
    18,35                            11,49                2011 年 12               不 适
    GMP 技改项目         否             18,355.69    3,195.30            62.61%                         0.00           否
    5.69                             1.85                月 31 日                 用
    5
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    24,51                           1,125            2013 年 12          不 适
    异地建厂             否               24,516.27        0.00           4.59%                 0.00           否
    6.27                             .16            月 31 日            用
    42,87                           12,61
    承诺投资项目小计      -               42,871.96    3,195.30             -           -       0.00     -          -
    1.96                            7.01
    超募资金投向
    购置空港 Max 企业             13,75                           9,888            2011 年 12          不 适
    否               13,758.00      63.42            71.87%                0.00           否
    园区房产                       8.00                             .24            月 31 日            用
    拟收购本公司合营
    公司广州市新花城              3,380                           338.0            2011 年 09          不 适
    否                3,380.00     338.00            10.00%                0.00           否
    生物科技有限公司                .00                               0            月 30 日            用
    20%股权
    对经纬医药进行增              9,820                           9,820   100.00   2010 年 09          不 适
    否                9,820.00        0.00                                 0.00           否
    资                              .00                             .00       %    月 17 日            用
    购买化合物 SX004
    6,500                           4,500            2011 年 09          不 适
    及其衍生药物美迪     否                6,500.00        0.00           69.23%                0.00           否
    .00                             .00            月 30 日            用
    替尼的所有权
    对山东誉衡药业投              8,305                           6,000            2012 年 06          不 适
    否                8,305.88    6,000.00           72.24%                0.00           否
    资                              .88                             .00            月 30 日            用
    对菏泽竣博医药增              1,000                           1,000   100.00   2011 年 06          不 适
    否                1,000.00    1,000.00                                 0.00           否
    资                              .00                             .00       %    月 30 日            用
    科研开发、同行业并
    73,01                                                                不 适
    购、补充流动资金及   否               73,014.16        0.00    0.00   0.00%                 0.00           否
    4.16                                                                用
    其他
    归还银行贷款(如              9,200                           9,200   100.00
    -                9,200.00        0.00                         -       -        -          -
    有)                      .00                             .00       %
    补充流动资金(如
    -                                                             -       -        -          -
    有)
    124,9   124,978.0               40,74
    超募资金投向小计      -                            7,401.42             -           -       0.00     -          -
    78.04           4                6.24
    167,8   167,850.0               53,36
    合计           -                           10,596.72             -           -       0.00     -          -
    50.00           0                3.25
    异地建厂项目原计划在募集资金到位后,固定资产投资基本在 2 年内完成。公司于 2009 年 10 月与
    黑龙江省哈尔滨市呼兰国土资源局就该土地签订了《国有土地使用权出让合同》,并已于 2010 年 7
    未达到计划进度或
    月支付了全部土地受让款项。但该地块所属开发区未及时将建筑附着物及遗留问题清理完毕,致使
    预计收益的情况和
    异地建厂项目被拖延了进度,为此公司一直在与开发区协商、督促解决。与此同时,2011 年 3 月国
    原因(分具体项目)
    家药监局颁布了新版 GMP 执行标准,提升了对原有生产条件及新建项目的生产控制标准,公司拟对
    原方案的审查和设计调整,从而影响了异地建厂项目的整体进度。
    项目可行性发生重
    不适用
    大变化的情况说明
    适用
    1、根据本公司第一届董事会第十五次会议及 2010 年第二次临时股东大会审议通过,利用募集资金
    超额部分中 9,200.00 万元偿还银行借款。,2010 年 11 月 26 日已全部支付上述借款。
    2、根据本公司第一届董事会第十五次会议及 2010 年第二次临时股东大会审议通过,利用募集资金
    超额部分中 9,820 万元增加全资子公司哈尔滨誉衡经纬医药发展有限公司注册资本,2010 年 9 月 6
    日已全部支付上述款项。
    超募资金的金额、用
    途及使用进展情况     3、根据本公司第一届董事会第十五次会议及 2010 年第二次临时股东大会审议通过,利用募集资金
    超额部分中 13,758.00 万元用于购置北京分公司及研发中心办公用地及房屋,截止 2011 年 6 月 30 日,
    已支付 9,888.24 万元。
    4、根据本公司第一届董事会第十八次会议及 2010 年第三次临时股东大会审议通过,利用募集资金
    超额部分中 6,500 万元用于购买化合物 SX004 及其衍生药物美迪替尼的所有权,截止 2011 年 6 月 30
    日,已支付上述款项 4,500 万。报告期内美迪替尼已获得欧洲、美国、加拿大、日本、印度、韩国、
    俄罗斯、非洲等十多个国家及区域一体化组织的专利认证。
    6
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    5、根据 2010 年 12 月 8 日公司第一届董事会第二十次会议审议通过,誉衡药业拟使用不超过人民币
    3,380 万元超募资金收购公司合营公司广州新花城生物科技有限公司 20%股权,截止 2011 年 6 月 30
    日报告期内已支付股权竞拍诚意金款 338 万元。,截至本报告公告日,公司已将全部股权转让款支付
    完毕,工商变更登记正在办理中。
    6、根据 2011 年 5 月 9 日公司第一届董事会第二十五次会议审议通过,誉衡药业使用 8,305.88 万元
    于山东省菏泽市建设原料药厂。,截止 2011 年 6 月 30 日报告期内已支付 6000 万元。
    7、根据 2011 年 5 月 9 日公司第一届董事会第二十五次会议审议通过,誉衡药业使用 1,000 万元用于
    对菏泽市牡丹区竣博医药有限公司增资。截至止 2011 年 6 月 30 日,已全部支付上述款项。
    募集资金投资项目
    不适用
    实施地点变更情况
    募集资金投资项目
    不适用
    实施方式调整情况
    募集资金投资项目        适用
    先期投入及置换情
    况                本公司上市前由自筹资金预先垫付募投项目支出 37,477,804.05 元,上市后从募集资金专户进行置换。
    用闲置募集资金暂
    时补充流动资金情        不适用
    况
    项目实施出现募集
    资金结余的金额及        不适用
    原因
    截止 2011 年 6 月 30 日,募集资金尚未使用的金额 115,211.15 万元,占全部募集资金净额 167,850.00
    尚未使用的募集资        万元的 68.64%,募投项目内的资金正按原计划稳妥执行,剩余超募资金将继续在超额募集资金专项
    金用途及去向          账户管理,公司将结合发展规划及实际生产经营需要投资于公司的主营业务,妥善安排其余超募资
    金的使用计划,提交董事会审议通过后及时披露。
    募集资金使用及披
    露中存在的问题或        无。
    其他情况
    5.6.2 变更募集资金投资项目情况表
    □ 适用 √ 不适用
    5.7 董事会下半年的经营计划修改计划
    □ 适用 √ 不适用
    5.8 对 2011 年 1-9 月经营业绩的预计
    2011 年 1-9 月预计的经营业
    归属于上市公司股东的净利润比上年同期下降幅度小于 50%
    绩
    2011 年 1-9 月净利润同比变      归属于上市公司股东的净利润比上年同期下降幅
    0.00%     ~~          30.00%
    动幅度的预计范围                度为:
    2010 年 1-9 月经营业绩          归属于上市公司股东的净利润(元):                                        97,608,376.44
    1、注射用头孢米诺钠未按计划量产影响了报告期销售业绩
    业绩变动的原因说明              2、受国家药品政策和行业内激烈的市场竞争,部分产品销售价格下调,造成相关产品毛利率
    同比下降。
    7
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    5.9 公司董事会对会计师事务所本报告期“非标准审计报告”的说明
    □ 适用 √ 不适用
    5.10 公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明
    □ 适用 √ 不适用
    §6 重要事项
    6.1 收购、出售资产及资产重组
    6.1.1 收购资产
    √ 适用 □ 不适用
    单位:万元
    与交
    自购买日起                                 所涉    所涉    易对
    本年初至报
    至报告期末                                 及的    及的    方的
    告期末为公
    为公司贡献                 是否            资产    债权    关联
    交易对方                                                    司贡献的净
    被收购或                 交易价    的净利润                   为关     定价   产权    债务    关系
    或最终控                购买日                              利润(适用
    置入资产                   格      (适用于非                 联交     原则   是否    是否    (适
    制方                                                      于同一控制
    同一控制下                 易              已全    已全    用关
    下的企业合
    的企业合                                   部过    部转    联交
    并)
    并)                                       户      移    易情
    形)
    菏泽市牡
    收益
    丹区竣博
    法评                   非关
    医药有限   2011 年 04
    曾伟强                               200.00         -5.83         0.00   否      估与    是     是      联关
    公司       月 30 日
    协商                   系
    100%股
    定价
    权
    6.1.2 出售资产
    □ 适用 √ 不适用
    6.1.3 自资产重组报告书或收购出售资产公告刊登后,该事项的进展情况及对报告期经营成果与财务状况
    的影响
    √ 适用 □ 不适用
    2011 年 4 月 30 日收购菏泽市牡丹区竣博医药有限公司全部股权并已办理工商变更手续。截止报告期末贡献收入为 0,贡献
    利润为-5.83 万。
    6.2 担保事项
    □ 适用 √ 不适用
    6.3 非经营性关联债权债务往来
    □ 适用 √ 不适用
    8
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    6.4 重大诉讼仲裁事项
    √ 适用 □ 不适用
    关于代理产品“注射用哌拉西林钠舒巴坦钠”未决诉讼事项:
    2010 年 6 月 21 日,公司及全资子公司哈尔滨誉衡经纬医药发展有限公司收到湖北省武汉市中级人民法院送达的民事
    应诉通知书(【2010】武知初字第 309 号)。案由为湘北威尔曼制药有限公司(以下简称“湘北威尔曼”)诉公司代理四川制
    药的哌拉西林钠舒巴坦钠发明专利权纠纷,本次诉讼涉及金额 5,000 万元以及相关费用 50 万元。相关案情已于 2010 年 6 月
    21 日公司上市公告书中予以披露,并刊登于当日的《证券时报》、《中国证券报》、《上海证券报》、《证券日报》以及巨潮资
    讯网(http://www.cninfo.com.cn)。
    2011 年 3 月 21 日,诉讼原告湘北威尔曼向武汉中院提出撤诉申请。武汉中院认为原告湘北威尔曼提出的撤诉申请,符合
    法律规定,应予准许。武汉中院同意湘北威尔曼的撤诉申请,诉讼费用由原告承担。
    上述诉讼公告的事项对本公司本期利润不产生影响。
    备查文件:武汉中院(2010)武知初字第 309 号《民事裁定书》。
    6.5 其他重大事项及其影响和解决方案的分析说明
    □ 适用 √ 不适用
    6.5.1 证券投资情况
    □ 适用 √ 不适用
    6.5.2 持有其他上市公司股权情况
    □ 适用 √ 不适用
    6.5.3 大股东及其附属企业非经营性资金占用及清偿情况表
    □ 适用 √ 不适用
    6.5.4 公司、股东及实际控制人承诺事项履行情况
    上市公司及其董事、监事和高级管理人员、公司持股 5%以上股东及其实际控制人等有关方在报告期内或持续到报告期内的
    以下承诺事项
    □ 适用 √ 不适用
    6.5.5 董事会本次利润分配或资本公积金转增股本预案
    □ 适用 √ 不适用
    6.5.6 其他综合收益细目
    单位:元
    项目                                  本期发生额                      上期发生额
    1.可供出售金融资产产生的利得(损失)金额
    减:可供出售金融资产产生的所得税影响
    前期计入其他综合收益当期转入损益的净额
    小计
    2.按照权益法核算的在被投资单位其他综合收益中所
    9
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    享有的份额
    减:按照权益法核算的在被投资单位其他综合收益中
    所享有的份额产生的所得税影响
    前期计入其他综合收益当期转入损益的净额
    小计
    3.现金流量套期工具产生的利得(或损失)金额
    减:现金流量套期工具产生的所得税影响
    前期计入其他综合收益当期转入损益的净额
    转为被套期项目初始确认金额的调整额
    小计
    4.外币财务报表折算差额
    减:处置境外经营当期转入损益的净额
    小计
    5.其他
    减:由其他计入其他综合收益产生的所得税影响
    前期其他计入其他综合收益当期转入损益的净额
    小计
    合计                                                                      0.00                           0.00
    6.6 报告期接待调研、沟通、采访等活动情况表
    接待时间         接待地点                  接待方式       接待对象           谈论的主要内容及提供的资料
    2011 年 03 月
    北京办公区                实地调研        陈斌               公司经营情况与发展规划
    04 日
    2011 年 03 月
    北京办公区                实地调研        李平祝             公司经营情况与发展规划
    04 日
    2011 年 03 月
    北京办公区                实地调研        高兰君             公司经营情况与发展规划
    04 日
    2011 年 03 月
    北京办公区                实地调研        张其立             公司经营情况与发展规划
    04 日
    2011 年 03 月
    哈尔滨办公区              实地调研        彭金聪             公司经营情况
    14 日
    2011 年 03 月
    哈尔滨办公区              实地调研        夏帅               公司经营情况
    14 日
    §7 财务报告
    7.1 审计意见
    财务报告                     √未经审计   □审计
    7.2 财务报表
    7.2.1 资产负债表
    编制单位:哈尔滨誉衡药业股份有限公司                        2011 年 06 月 30 日                        单位:
    10
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    元
    期末余额                                  年初余额
    项目
    合并                  母公司              合并                  母公司
    流动资产:
    货币资金                     1,450,381,092.01       1,315,513,585.90   1,538,322,600.66       1,431,088,155.41
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                        4,438,025.36           3,517,577.36         300,000.00             300,000.00
    应收账款                       13,810,735.96          11,595,992.68      18,221,032.27          17,498,788.99
    预付款项                      201,299,405.06         187,448,728.84     148,541,102.58         139,386,782.26
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                     73,071,683.66          62,992,821.57      76,799,244.94          55,929,255.23
    买入返售金融资产
    存货                           66,293,837.31          46,947,857.00      53,264,926.23          26,291,806.38
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                     1,809,294,779.36       1,628,016,563.35   1,835,448,906.68       1,670,494,788.27
    非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                   68,303,019.91         248,553,019.91      69,232,696.56         177,482,696.56
    投资性房地产
    固定资产                      223,281,541.07         211,388,885.11     223,213,994.30         214,719,922.43
    在建工程                       33,608,514.18          33,608,514.18      30,810,684.94          30,810,684.94
    工程物资
    固定资产清理                        3,935.83               3,935.83
    生产性生物资产
    油气资产
    无形资产                       23,458,117.92          23,453,197.80      25,051,648.89          25,045,088.79
    开发支出                        8,831,046.15           8,058,429.09       7,231,149.90           6,458,532.84
    商誉                            2,394,312.14
    长期待摊费用                    1,548,871.77           1,046,569.65       2,067,378.99           1,315,368.81
    递延所得税资产                  1,823,803.67              15,997.75       1,413,587.97              14,345.97
    其他非流动资产
    非流动资产合计                    363,253,162.64         526,128,549.32     359,021,141.55         455,846,640.34
    资产总计                         2,172,547,942.00       2,154,145,112.67   2,194,470,048.23       2,126,341,428.61
    11
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    流动负债:
    短期借款
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据
    应付账款                       12,882,976.08      10,529,623.17      12,665,410.36      11,053,105.34
    预收款项                          981,334.30                          3,831,334.30
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                      951,009.26         208,978.75         451,515.87          27,307.04
    应交税费                       21,247,836.70      15,429,914.54      26,694,092.40      19,405,478.88
    应付利息
    应付股利
    其他应付款                     21,858,367.99      14,980,524.33      30,085,237.39      21,155,989.80
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                       57,921,524.33      41,149,040.79      73,727,590.32      51,641,881.06
    非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
    非流动负债合计
    负债合计                           57,921,524.33      41,149,040.79      73,727,590.32      51,641,881.06
    所有者权益(或股东权益):
    实收资本(或股本)            280,000,000.00     280,000,000.00     140,000,000.00     140,000,000.00
    资本公积                     1,507,868,180.53   1,507,619,070.29   1,647,868,180.53   1,647,619,070.29
    减:库存股
    专项储备
    盈余公积                       35,721,747.62      35,721,747.62      35,721,747.62      35,721,747.62
    一般风险准备
    未分配利润                    291,036,489.52     289,655,253.97     297,152,529.76     251,358,729.64
    外币报表折算差额
    归属于母公司所有者权益合         2,114,626,417.67   2,112,996,071.88   2,120,742,457.91   2,074,699,547.55
    12
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    计
    少数股东权益
    所有者权益合计                   2,114,626,417.67         2,112,996,071.88         2,120,742,457.91       2,074,699,547.55
    负债和所有者权益总计             2,172,547,942.00         2,154,145,112.67         2,194,470,048.23       2,126,341,428.61
    7.2.2 利润表
    编制单位:哈尔滨誉衡药业股份有限公司                               2011 年 1-6 月                              单位:元
    本期金额                                        上期金额
    项目
    合并                  母公司                    合并                  母公司
    一、营业总收入                    254,966,833.88           128,999,925.08           236,145,222.90         119,266,481.35
    其中:营业收入                    254,966,833.88           128,999,925.08           236,145,222.90         119,266,481.35
    利息收入
    已赚保费
    手续费及佣金收入
    二、营业总成本                    177,728,443.97            64,603,160.20           162,494,019.74          60,528,020.17
    其中:营业成本                    124,786,075.12            32,633,323.07           108,368,584.67          30,342,720.43
    利息支出
    手续费及佣金支出
    退保金
    赔付支出净额
    提取保险合同准备金
    净额
    保单红利支出
    分保费用
    营业税金及附加               2,882,974.97            1,813,116.58              250,350.16
    销售费用                  22,292,345.17             8,820,612.17            30,170,638.62          10,944,759.96
    管理费用                  31,622,827.79            24,252,448.26            22,538,499.51          16,856,490.61
    财务费用                     -3,077,726.64          -2,929,554.17            2,318,359.03           2,331,097.08
    资产减值损失                  -778,052.44              13,214.29             -1,152,412.25             52,952.09
    加:公允价值变动收益(损
    失以“-”号填列)
    投资收益(损失以“-”
    -929,676.65          52,015,859.10              -660,639.90            -660,639.90
    号填列)
    其中:对联营企业和
    -929,676.65            -929,676.65              -660,639.90            -660,639.90
    合营企业的投资收益
    汇兑收益(损失以“-”号
    填列)
    三、营业利润(亏损以“-”号
    76,308,713.26           116,412,623.98            72,990,563.26          58,077,821.28
    填列)
    加:营业外收入                      43,170.00              57,794.48             1,006,000.00           1,002,000.00
    减:营业外支出                     108,798.84             108,798.84                 1,000.00
    其中:非流动资产处置损
    失
    四、利润总额(亏损总额以“-”      76,243,084.42           116,361,619.62            73,995,563.26          59,079,821.28
    13
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    号填列)
    减:所得税费用                12,359,124.66          8,065,095.29          10,971,769.21         7,467,557.64
    五、净利润(净亏损以“-”号
    63,883,959.76        108,296,524.33          63,023,794.05        51,612,263.64
    填列)
    归属于母公司所有者的
    63,883,959.76        108,296,524.33          63,023,794.05        51,612,263.64
    净利润
    少数股东损益
    六、每股收益:
    (一)基本每股收益                    0.23                 0.39                   0.60                 0.49
    (二)稀释每股收益                    0.23                 0.39                   0.60                 0.49
    七、其他综合收益
    八、综合收益总额                   63,883,959.76        108,296,524.33          63,023,794.05        51,612,263.64
    归属于母公司所有者的
    63,883,959.76        108,296,524.33          63,023,794.05        51,612,263.64
    综合收益总额
    归属于少数股东的综合
    收益总额
    本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元。
    7.2.3 现金流量表
    编制单位:哈尔滨誉衡药业股份有限公司                           2011 年 1-6 月                          单位:元
    本期金额                                    上期金额
    项目
    合并              母公司                  合并                母公司
    一、经营活动产生的现金流
    量:
    销售商品、提供劳务收到
    292,385,262.73        158,475,570.78         291,104,310.12       145,351,472.62
    的现金
    客户存款和同业存放款
    项净增加额
    向中央银行借款净增加
    额
    向其他金融机构拆入资
    金净增加额
    收到原保险合同保费取
    得的现金
    收到再保险业务现金净
    额
    保户储金及投资款净增
    加额
    处置交易性金融资产净
    增加额
    收取利息、手续费及佣金
    的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还
    收到其他与经营活动有
    63,304,123.40          1,827,644.98          42,553,964.64         4,590,835.03
    关的现金
    14
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    经营活动现金流入小
    355,689,386.13   160,303,215.76   333,658,274.76   149,942,307.65
    计
    购买商品、接受劳务支付
    161,949,590.75    62,166,598.63   126,980,478.54    21,938,724.80
    的现金
    客户贷款及垫款净增加
    额
    存放中央银行和同业款
    项净增加额
    支付原保险合同赔付款
    项的现金
    支付利息、手续费及佣金
    的现金
    支付保单红利的现金
    支付给职工以及为职工
    21,149,191.60    13,671,377.54    16,568,732.09    10,799,874.54
    支付的现金
    支付的各项税费              40,788,983.04    26,709,193.20    38,779,392.75    28,686,013.67
    支付其他与经营活动有
    88,215,545.00    14,820,129.77   107,851,086.12    23,261,463.09
    关的现金
    经营活动现金流出小
    312,103,310.39   117,367,299.14   290,179,689.50    84,686,076.10
    计
    经营活动产生的现
    43,586,075.74    42,935,916.62    43,478,585.26    65,256,231.55
    金流量净额
    二、投资活动产生的现金流
    量:
    收回投资收到的现金
    取得投资收益收到的现
    52,945,535.75
    金
    处置固定资产、无形资产
    和其他长期资产收回的现金                1,625.00         1,625.00
    净额
    处置子公司及其他营业
    单位收到的现金净额
    收到其他与投资活动有
    关的现金
    投资活动现金流入小
    1,625.00    52,947,160.75
    计
    购建固定资产、无形资产
    58,443,152.98    51,554,518.34    27,761,777.07    21,299,826.77
    和其他长期资产支付的现金
    投资支付的现金               3,380,000.00    75,380,000.00
    质押贷款净增加额
    取得子公司及其他营业
    1,981,351.31
    单位支付的现金净额
    支付其他与投资活动有
    关的现金
    投资活动现金流出小
    63,804,504.29   126,934,518.34    27,761,777.07    21,299,826.77
    计
    投资活动产生的现
    -63,802,879.29   -73,987,357.59   -27,761,777.07   -21,299,826.77
    金流量净额
    三、筹资活动产生的现金流
    15
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    量:
    吸收投资收到的现金                                              1,688,250,000.00   1,688,250,000.00
    其中:子公司吸收少数股
    东投资收到的现金
    取得借款收到的现金
    发行债券收到的现金
    收到其他与筹资活动有
    2,463,260.99      12,463,260.99
    关的现金
    筹资活动现金流入小
    2,463,260.99      12,463,260.99    1,688,250,000.00   1,688,250,000.00
    计
    偿还债务支付的现金
    分配股利、利润或偿付利
    70,187,966.09      70,187,966.09       2,582,489.00       2,582,489.00
    息支付的现金
    其中:子公司支付给少数
    股东的股利、利润
    支付其他与筹资活动有
    26,798,423.44       4,910,087.63      14,901,800.63
    关的现金
    筹资活动现金流出小
    70,187,966.09      96,986,389.53       7,492,576.63      17,484,289.63
    计
    筹资活动产生的现
    -67,724,705.10     -84,523,128.54   1,680,757,423.37   1,670,765,710.37
    金流量净额
    四、汇率变动对现金及现金等
    价物的影响
    五、现金及现金等价物净增加
    -87,941,508.65    -115,574,569.51   1,696,474,231.56   1,714,722,115.15
    额
    加:期初现金及现金等价
    1,538,322,600.66   1,431,088,155.41     87,965,514.20      52,136,840.82
    物余额
    六、期末现金及现金等价物余
    1,450,381,092.01   1,315,513,585.90   1,784,439,745.76   1,766,858,955.97
    额
    16
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    7.2.4 合并所有者权益变动表
    编制单位:哈尔滨誉衡药业股份有限公司                                                      2011 半年度                                                         单位:元
    本期金额                                                                     上年金额
    归属于母公司所有者权益                                                       归属于母公司所有者权益
    实收                                                               所有      实收                                                                   所有
    少数                                                                             少数
    项目            资本            减:                  一般   未分                  者权      资本            减:                  一般   未分                      者权
    资本           专项   盈余                          股东                     资本           专项   盈余                              股东
    (或            库存                  风险   配利    其他          益合      (或            库存                  风险   配利     其他             益合
    公积           储备   公积                          权益                     公积           储备   公积                              权益
    股             股                    准备    润                    计        股             股                    准备    润                        计
    本)                                                                         本)
    1,647                                                      2,120
    140,0                         35,72          297,1                           105,0   4,368                 23,31          154,8                     287,5
    ,868,                                                      ,742,
    一、上年年末余额           00,00                         1,747          52,52                           00,00   ,180.                 4,725          46,51                     29,41
    180.5                                                      457.9
    0.00                           .62           9.76                            0.00     53                    .83           1.82                      8.18
    3                                                             1
    加:会计政策变更
    前期差错更正
    其他
    1,647                                                      2,120
    140,0                         35,72          297,1                           105,0   4,368                 23,31          154,8                     287,5
    ,868,                                                      ,742,
    二、本年年初余额           00,00                         1,747          52,52                           00,00   ,180.                 4,725          46,51                     29,41
    180.5                                                      457.9
    0.00                           .62           9.76                            0.00     53                    .83           1.82                      8.18
    3                                                             1
    1,643                                                          1,833
    140,0   -140,                                -6,11                 -6,11     35,00                         12,40          142,3
    三、本年增减变动金额(减                                                                                        ,500,                                                          ,213,
    00,00   000,0   0.00   0.00    0.00   0.00   6,040   0.00   0.00   6,040     0,000                         7,021          06,01
    少以“-”号填列)                                                                                               000.0                                                          039.7
    0.00   00.00                                  .24                   .24       .00                           .79           7.94
    0                                                                 3
    17
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    63,88                 63,88                           154,7   154,7
    (一)净利润                                                      3,959                 3,959                           13,03   13,03
    .76                   .76                            9.73    9.73
    (二)其他综合收益
    63,88                 63,88                           154,7   154,7
    上述(一)和(二)小
    3,959                 3,959                           13,03   13,03
    计
    .76                   .76                            9.73    9.73
    1,643                   1,678
    35,00
    (三)所有者投入和减                                                                                    ,500,                   ,500,
    0,000
    少资本                                                                                                       000.0                   000.0
    .00
    0                       0
    1,643                   1,678
    35,00
    ,500,                   ,500,
    1.所有者投入资本                                                                             0,000
    000.0                   000.0
    .00
    0                       0
    2.股份支付计入所有
    者权益的金额
    3.其他
    -70,0                 -70,0                   12,40   -12,4
    (四)利润分配          0.00   0.00   0.00   0.00   0.00   0.00   00,00   0.00   0.00   00,00                   7,021   07,02
    0.00                  0.00                     .79    1.79
    12,40   -12,4
    1.提取盈余公积                                                                                               7,021   07,02
    .79    1.79
    2.提取一般风险准备
    18
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    -70,0                 -70,0
    3.对所有者(或股东)
    00,00                 00,00
    的分配
    0.00                  0.00
    4.其他
    140,0   -140,
    (五)所有者权益内部
    00,00   000,0   0.00   0.00    0.00   0.00    0.00   0.00   0.00    0.00
    结转
    0.00   00.00
    140,0   -140,
    1.资本公积转增资本
    00,00   000,0
    (或股本)
    0.00   00.00
    2.盈余公积转增资本
    (或股本)
    3.盈余公积弥补亏损
    4.其他
    (六)专项储备
    1.本期提取
    2.本期使用
    (七)其他
    1,507                                                      2,114           1,647                   2,120
    280,0                         35,72          291,0                         140,0           35,72   297,1
    ,868,                                                      ,626,           ,868,                   ,742,
    四、本期期末余额               00,00           0.00   0.00   1,747   0.00   36,48   0.00   0.00           00,00           1,747   52,52
    180.5                                                      417.6           180.5                   457.9
    0.00                           .62           9.52                          0.00             .62    9.76
    3                                                          7               3                       1
    19
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    7.2.5 母公司所有者权益变动表
    编制单位:哈尔滨誉衡药业股份有限公司                                                               2011 半年度                                                        单位:元
    本期金额                                                                            上年金额
    实收资                                                                  所有者      实收资                                                                所有者
    项目                      资本公      减:库   专项储   盈余公    一般风   未分配                             资本公      减:库   专项储   盈余公    一般风   未分配
    本(或                                                                  权益合      本(或                                                                权益合
    积        存股       备       积      险准备   利润                                 积        存股       备       积      险准备   利润
    股本)                                                                    计        股本)                                                                  计
    140,00    1,647,6                                          251,35       2,074,6     105,00                                                     139,69     272,12
    35,721,                                               4,119,0                       23,314,
    一、上年年末余额            0,000.0   19,070.       0.00     0.00               0.00   8,729.6      99,547.     0,000.0                                                    5,533.5    9,329.7
    747.62                                                 70.29                        725.83
    0           29                                               4            55        0                                                            8          0
    加:会计政策变更                                                                                  0.00                                                                             0.00
    前期差错更正                                                                                      0.00                                                                             0.00
    其他                                                                                              0.00                                                                             0.00
    140,00    1,647,6                                          251,35       2,074,6     105,00                                                     139,69     272,12
    35,721,                                               4,119,0                       23,314,
    二、本年年初余额            0,000.0   19,070.       0.00     0.00               0.00   8,729.6      99,547.     0,000.0                 0.00     0.00               0.00   5,533.5    9,329.7
    747.62                                                 70.29                        725.83
    0           29                                               4            55        0                                                            8          0
    140,00    -140,00                                                                             1,643,5                                          111,66     1,802,5
    三、本年增减变动金额(减                                                               38,296,      38,296,     35,000,                                 12,407,
    0,000.0   0,000.0       0.00     0.00     0.00      0.00                                      00,000.       0.00     0.00               0.00   3,196.0    70,217.
    少以“-”号填列)                                                                      524.33        524.33     000.00                                  021.79
    0           0                                                                                   00                                               6          85
    108,29        108,29                                                                124,07     124,07
    (一)净利润                                                                      6,524.3      6,524.3                                                                0,217.8    0,217.8
    3            3                                                                      5          5
    (二)其他综合收益                                                                                0.00                                                                             0.00
    上述(一)和(二)小                                                              108,29        108,29                                                                124,07     124,07
    0.00       0.00       0.00     0.00     0.00      0.00                              0.00      0.00        0.00     0.00     0.00
    计                                                                                     6,524.3      6,524.3                                                                0,217.8    0,217.8
    20
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    3         3                                                            5         5
    1,643,5                                            1,678,5
    (三)所有者投入和减                                                                           35,000,
    0.00             00,000.   0.00   0.00     0.00    0.00      0.00   00,000.
    少资本                                                                                             000.00
    00                                                 00
    1,643,5                                            1,678,5
    35,000,
    1.所有者投入资本                                                                    0.00             00,000.                                            00,000.
    000.00
    00                                                 00
    2.股份支付计入所有
    0.00                                                                  0.00
    者权益的金额
    3.其他                                                                              0.00                                                                  0.00
    -70,000   -70,000                                     12,407,          -12,407
    (四)利润分配               0.00       0.00   0.00   0.00   0.00   0.00                         0.00      0.00    0.00   0.00             0.00               0.00
    ,000.00   ,000.00                                     021.79           ,021.79
    12,407,          -12,407
    1.提取盈余公积                                                                      0.00                                                                  0.00
    021.79           ,021.79
    2.提取一般风险准备                                                                  0.00                                                                  0.00
    3.对所有者(或股东)                                                   -70,000   -70,000
    0.00
    的分配                                                                         ,000.00   ,000.00
    4.其他                                                                              0.00                                                                  0.00
    140,00    -140,00
    (五)所有者权益内部
    0,000.0   0,000.0   0.00   0.00   0.00   0.00      0.00      0.00     0.00      0.00    0.00   0.00     0.00    0.00      0.00     0.00
    结转
    0         0
    140,00    -140,00
    1.资本公积转增资本
    0,000.0   0,000.0                                            0.00                                                                  0.00
    (或股本)
    0         0
    2.盈余公积转增资本                                                                  0.00                                                                  0.00
    21
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    (或股本)
    3.盈余公积弥补亏损                                                                  0.00                                                                   0.00
    4.其他                                                                              0.00                                                                   0.00
    (六)专项储备                                                                         0.00      0.00      0.00    0.00   0.00     0.00    0.00     0.00      0.00
    1.本期提取                                                                          0.00                                                                   0.00
    2.本期使用                                                                          0.00                                                                   0.00
    (七)其他
    280,00    1,507,6                                  289,65    2,112,9   140,00    1,647,6                                  251,35    2,074,6
    35,721,                                                                35,721,
    四、本期期末余额            0,000.0   19,070.   0.00   0.00             0.00   5,253.9   96,071.   0,000.0   19,070.   0.00   0.00             0.00   8,729.6   99,547.
    747.62                                                                 747.62
    0        29                                        7        88         0        29                                        4        55
    22
    哈尔滨誉衡药业股份有限公司 2011 年半年度报告摘要
    7.3 报表附注
    7.3.1 如果出现会计政策、会计估计变更或会计差错更正的,说明有关内容、原因及影响数
    □ 适用 √ 不适用
    7.3.2 如果财务报表合并范围发生重大变化的,说明原因及影响数
    √ 适用 □ 不适用
    2011 年 4 月 30 日本公司出资收购了菏泽市牡丹区竣博医药有限公司,并持有其股份的 100%,截止报告期末已办理工商变
    更手续。
    2011 年 5 月 19 日本公司出资设立了山东誉衡药业有限公司,并持有其股份的 100%,截止报告期末已办理工商注册手续。
    7.3.3 如果被出具非标准审计报告,列示涉及事项的有关附注
    □ 适用 √ 不适用
    哈尔滨誉衡药业股份有限公司
    法定代表人:朱吉满
    2011 年 8 月 30 日
    23